STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Summary

This is an open-label, phase 1b/2 trial. It is designed to identify the recommended phase 2 dose (RP2D) of STI-6129, and the safety and efficacy of this anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC) for the treatment of R/R T-ALL and AML who have exhausted standard of care treatment.

Timeline

Start

2022-08-16

Primary completion

2023-02-15

Completion

2023-02-15

Outcome

Outcome not reported

Stopped (Enrollment): “0 patient accrual”

Drugs

Indications